Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738616 | 0.86 | MEN1 (0.37) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL1352521 | 0.83 | MEN1 (0.37) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL5103879 | 0.77 | BTK (0.35) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL23750033 | 0.77 | MEN1 (0.36) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL5104037 | 0.76 | KMT2A (0.33) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL21119394 | 0.76 | CTSK (0.33) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL5097256 | 0.76 | MAPT (0.34) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL23268367 | 0.75 | KMT2A (0.35) | GAAMEN1MAPK1KMT2ACTSL | |
| SCHEMBL1516443 | 0.75 | MEN1 (0.36) | GAAMEN1MAPK1KMT2ABTK | |
| SCHEMBL9924136 | 0.73 | MEN1 (0.40) | GAAMEN1MAPK1KMT2ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439263-B2 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1598350-B1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | SERVIER LAB (FR) | 2007-07-11 | — | — | EP | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598350-A1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | LES LABORATOIRES SERVIER (FR) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | DPP4, DPP3, NR4A1 | GAA 3579/4885MEN1 3591/4885MAPK1 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.